Anti-Angiogenesis

Users can build upon the angiogenesis model in AIM DAX-1 chips to investigate factors that are anti-angiogenic. The inhibitors may include chemical entities, proteins, genetic regulators, mechanobiological factors, etc. 

Protocols

The DAX-1 chip design is suitable for anti-angiogenesis assays; however, the detailed protocols for the AIM chips are currently being developed. Please refer to the references below;  these papers used PDMS versions of the chip to conduct anti-angiogenesis assays.
Users can submit their protocols to be referenced in this section and given due credit.

References

  1. ​The stabilization effect of mesenchymal stem cells on the formation of microvascular networks in a microfluidic device. Yamamoto K, Tanimura K, Mabuchi Y, Matsuzaki Y, Chung S, Kamm RD, . . . Sudo R. J. Biomech. Sci. Eng., 2013. 8 (2):114-128
  2. Dll4-containing exosomes induce capillary sprout retraction in a 3D microenvironment. Sharghi-Namini S, Tan E, Ong L-LS, Ge R, Asada HH. Sci. Rep., 2014. 4:4031
  3. A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs. Kim C, Kasuya J, Jeon J, Chung S, Kamm RD. Lab Chip, 2015. 15 (1):301-310
  4. *Phthalimide Derivative Shows Anti-angiogenic Activity in a 3D Microfluidic Model and No Teratogenicity in Zebrafish Embryos. Mercurio A, Sharples L, Corbo F, Franchini C, Vacca A, Catalano A, Carocci A, Kamm RD, Pavesi A and Adriani G (2019)  Front. Pharmacol. 10:349. doi: 10.3389/fphar.2019.00349​
  5. *Isolinderalactone suppresses human glioblastoma growth and angiogenic activity in 3D microfluidic chip and in vivo mouse models. Park JH, Kim MJ, Kim WJ, Kwon KD, Ha KT, Choi BT, Lee SY and Shin HK. Cancer Letters (Mar 2020) DOI:10.1016/j.canlet.2020.03.009
Users can submit their publications to be referenced in this section.